ANI Pharmaceuticals Insider Sale: 1,763 Shares Disposed by SVP Davis

Rhea-AI Filing Summary

Krista Davis, SVP and Chief HR Officer of ANI Pharmaceuticals, Inc. (ANIP), reported the sale of 1,763 shares of ANI common stock on 08/22/2025. The shares were sold in multiple trades at prices ranging from $91.01 to $91.19, with a weighted average sales price reported as $91.10. After the transaction, Ms. Davis beneficially owned 62,896 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/25/2025. The filing identifies the reporter as an officer (SVP, Chief HR Officer).

Positive

• Timely and complete disclosure of an insider sale including transaction date, price range, weighted average price, and post-transaction ownership
• Clear identification of the reporting person and role (SVP, Chief HR Officer), aiding investor transparency

Negative

• Insider sale of 1,763 shares reduced direct beneficial ownership to 62,896 shares

Insights

Financial Analyst

TL;DR: Officer sold a small parcel of shares; filing documents the sale and current beneficial ownership.

The sale of 1,763 shares at a weighted average price of $91.10 reduces the officer's direct holdings to 62,896 shares. This Form 4 is a routine disclosure of an open-market sale; the filing provides clear price range and aggregate post-transaction ownership. No derivative transactions or additional compensatory grants are reported. From a trading-signals perspective, the data is factual and limited to a single disposal event without accompanying company-level operational or financial metrics.

Corporate Governance Expert

TL;DR: Timely SEC disclosure by an insider showing compliance; sale was executed and documented via attorney-in-fact.

The Form 4 shows compliance with Section 16 reporting: transaction date, price range, weighted average price, and post-transaction beneficial ownership are disclosed. The signature was executed by an attorney-in-fact, which is properly noted. The report contains no indications of a Rule 10b5-1 plan or other exemption. As presented, the filing documents a routine insider sale and fulfills disclosure obligations.

Insider Trade Summary

Net Seller: 1,763 shares ($160,609)

Net Sell 1 txn

Insider Davis Krista

Role SVP, CHIEF HR OFFICER

Sold 1,763 shs ($161K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,763	$91.10	$161K

Holdings After Transaction: Common Stock — 62,896 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Krista

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/22/2025		S		1,763	D	$91.1(1)	62,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $91.01 to $91.19. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Krista Davis, by attorney-in-fact Meredith W. Cook	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Krista Davis report on Form 4 for ANIP?

The Form 4 reports a sale of 1,763 shares of ANI Pharmaceuticals common stock executed on 08/22/2025.

At what price were the ANIP shares sold by the insider?

The shares were sold in multiple trades at prices ranging from $91.01 to $91.19, with a weighted average price of $91.10.

How many ANIP shares does Krista Davis beneficially own after the reported sale?

After the reported transaction, Krista Davis beneficially owned 62,896 shares.

When was the Form 4 for the ANIP transaction signed and by whom?

The Form 4 was signed on behalf of the reporting person by attorney-in-fact Meredith W. Cook on 08/25/2025.

Is there any indication the sale was part of a 10b5-1 trading plan?

No. The filing does not check or reference a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c) conditions.